Advanced search
1 file | 510.19 KB Add to list

Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy : a multi-institutional cohort from PSOGI and BIG-RENAPE

(2018) ANNALS OF SURGICAL ONCOLOGY. 25(6). p.1668-1675
Author
Organization
Abstract
Ovarian cancer is the most common deadly cancer of gynecologic origin. Patients often are diagnosed at advanced stage with peritoneal metastasis. There are many rare histologies of ovarian cancer; some have outcomes worse than serous ovarian cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can be considered for patients with recurrence. This study was designed to assess the impact of CRS and HIPEC on survival of patient with peritoneal metastasis from rare ovarian malignancy. A prospective, multicentric, international database was retrospectively searched to identify all patients with rare ovarian tumor (mucinous, clear cells, endometrioid, small cell hypercalcemic, and other) and peritoneal metastasis who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI) and BIG-RENAPE working group. The postoperative complications, long-term results, and principal prognostic factors were analyzed. The analysis included 210 patients with a median follow-up of 43.5 months. Median overall survival (OS) was 69.3 months, and the 5-year OS was 57.7%. For mucinous tumors, median OS and DFS were not reached at 5 years. For granulosa tumors, median overall survival was not reached at 5 years, and median DFS was 34.6 months. Teratoma or germinal tumor showed median overall survival and DFS that were not reached at 5 years. Differences in OS were not statistically significant between histologies (p = 0.383), whereas differences in DFS were (p < 0.001). CRS and HIPEC may increases long-term survival in selected patients with peritoneal metastasis from rare ovarian tumors especially in mucinous, granulosa, or teratoma histological subtypes.
Keywords
ONCOLOGY GROUP EXPERIENCE, GRANULOSA-CELL TUMOR, CLEAR-CELL, PSEUDOMYXOMA PERITONEI, PROGNOSTIC-FACTORS, CANCER, METAANALYSIS, SURVIVAL, HIPEC, APPENDICEAL

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 510.19 KB

Citation

Please use this url to cite or link to this publication:

MLA
Mercier, Frederic, Naoual Bakrin, David L Bartlett, et al. “Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy : a Multi-institutional Cohort from PSOGI and BIG-RENAPE.” ANNALS OF SURGICAL ONCOLOGY 25.6 (2018): 1668–1675. Print.
APA
Mercier, F., Bakrin, N., Bartlett, D. L., Goere, D., Quenet, F., Dumont, F., Heyd, B., et al. (2018). Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy : a multi-institutional cohort from PSOGI and BIG-RENAPE. ANNALS OF SURGICAL ONCOLOGY, 25(6), 1668–1675.
Chicago author-date
Mercier, Frederic, Naoual Bakrin, David L Bartlett, Diane Goere, François Quenet, Frederic Dumont, Bruno Heyd, et al. 2018. “Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy : a Multi-institutional Cohort from PSOGI and BIG-RENAPE.” Annals of Surgical Oncology 25 (6): 1668–1675.
Chicago author-date (all authors)
Mercier, Frederic, Naoual Bakrin, David L Bartlett, Diane Goere, François Quenet, Frederic Dumont, Bruno Heyd, Karine Abboud, Christelle Marolho, Laurent Villeneuve, Olivier Glehen, the PSOGI Working Group, and Wim Ceelen. 2018. “Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy : a Multi-institutional Cohort from PSOGI and BIG-RENAPE.” Annals of Surgical Oncology 25 (6): 1668–1675.
Vancouver
1.
Mercier F, Bakrin N, Bartlett DL, Goere D, Quenet F, Dumont F, et al. Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy : a multi-institutional cohort from PSOGI and BIG-RENAPE. ANNALS OF SURGICAL ONCOLOGY. 2018;25(6):1668–75.
IEEE
[1]
F. Mercier et al., “Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy : a multi-institutional cohort from PSOGI and BIG-RENAPE,” ANNALS OF SURGICAL ONCOLOGY, vol. 25, no. 6, pp. 1668–1675, 2018.
@article{8583505,
  abstract     = {Ovarian cancer is the most common deadly cancer of gynecologic origin. Patients often are diagnosed at advanced stage with peritoneal metastasis. There are many rare histologies of ovarian cancer; some have outcomes worse than serous ovarian cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can be considered for patients with recurrence. This study was designed to assess the impact of CRS and HIPEC on survival of patient with peritoneal metastasis from rare ovarian malignancy. 
A prospective, multicentric, international database was retrospectively searched to identify all patients with rare ovarian tumor (mucinous, clear cells, endometrioid, small cell hypercalcemic, and other) and peritoneal metastasis who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI) and BIG-RENAPE working group. The postoperative complications, long-term results, and principal prognostic factors were analyzed. 
The analysis included 210 patients with a median follow-up of 43.5 months. Median overall survival (OS) was 69.3 months, and the 5-year OS was 57.7%. For mucinous tumors, median OS and DFS were not reached at 5 years. For granulosa tumors, median overall survival was not reached at 5 years, and median DFS was 34.6 months. Teratoma or germinal tumor showed median overall survival and DFS that were not reached at 5 years. Differences in OS were not statistically significant between histologies (p = 0.383), whereas differences in DFS were (p < 0.001). 
CRS and HIPEC may increases long-term survival in selected patients with peritoneal metastasis from rare ovarian tumors especially in mucinous, granulosa, or teratoma histological subtypes.},
  author       = {Mercier, Frederic and Bakrin, Naoual and Bartlett, David L and Goere, Diane and Quenet, François and Dumont, Frederic and Heyd, Bruno and Abboud, Karine and Marolho, Christelle and Villeneuve, Laurent and Glehen, Olivier and PSOGI Working Group, the and Ceelen, Wim},
  issn         = {1068-9265},
  journal      = {ANNALS OF SURGICAL ONCOLOGY},
  keywords     = {ONCOLOGY GROUP EXPERIENCE,GRANULOSA-CELL TUMOR,CLEAR-CELL,PSEUDOMYXOMA PERITONEI,PROGNOSTIC-FACTORS,CANCER,METAANALYSIS,SURVIVAL,HIPEC,APPENDICEAL},
  language     = {eng},
  number       = {6},
  pages        = {1668--1675},
  title        = {Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy : a multi-institutional cohort from PSOGI and BIG-RENAPE},
  url          = {http://dx.doi.org/10.1245/s10434-018-6464-z},
  volume       = {25},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: